Patents by Inventor Martin MacPhee

Martin MacPhee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160213807
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.
    Type: Application
    Filed: April 2, 2016
    Publication date: July 28, 2016
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20160213806
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 28, 2016
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20160106883
    Abstract: Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall, Shirley Miekka
  • Patent number: 9259503
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: February 16, 2016
    Assignee: STB, LTD.
    Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall
  • Publication number: 20150367019
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques.
    Type: Application
    Filed: March 12, 2015
    Publication date: December 24, 2015
    Inventors: Martin MacPhee, Dawson Beall, Jennifer Brichetti, Belinda Wilmer
  • Publication number: 20150328053
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.
    Type: Application
    Filed: January 18, 2015
    Publication date: November 19, 2015
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20150289861
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques.
    Type: Application
    Filed: March 12, 2015
    Publication date: October 15, 2015
    Inventors: Martin MacPhee, Dawson Beall, Jennifer Brichetti, Belinda Wilmer
  • Patent number: 9131929
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: September 15, 2015
    Assignee: STB, Ltd.
    Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall
  • Publication number: 20150132363
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.
    Type: Application
    Filed: January 18, 2015
    Publication date: May 14, 2015
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20150118284
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.
    Type: Application
    Filed: December 24, 2014
    Publication date: April 30, 2015
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20130287837
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 31, 2013
    Inventors: Martin MacPhee, Dawson Beall
  • Patent number: 8445009
    Abstract: Disclosed are processes for preparing solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen and liquid compositions useful for preparing the haemostatic layer(s) of these dressings or for treating wounded tissue in a mammal.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: May 21, 2013
    Assignee: STB, Ltd
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20120321692
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.
    Type: Application
    Filed: February 7, 2012
    Publication date: December 20, 2012
    Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall
  • Publication number: 20120150087
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.
    Type: Application
    Filed: February 2, 2012
    Publication date: June 14, 2012
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20120148659
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.
    Type: Application
    Filed: February 2, 2012
    Publication date: June 14, 2012
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20120148658
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.
    Type: Application
    Filed: February 1, 2012
    Publication date: June 14, 2012
    Inventors: Martin MacPhee, Dawson Beall
  • Publication number: 20110196421
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.
    Type: Application
    Filed: April 5, 2011
    Publication date: August 11, 2011
    Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall
  • Publication number: 20090075891
    Abstract: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.
    Type: Application
    Filed: August 6, 2008
    Publication date: March 19, 2009
    Inventors: Martin MacPhee, Jerry Kanellos, Belinda Wilmer, Dawson Beall
  • Publication number: 20080080998
    Abstract: Methods are disclosed for sterilizing tissue to reduce the level of one or more active biological contaminants or pathogens therein, such as viruses, bacteria, (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), yeasts, molds, fungi, prions or similar agents responsible, alone or in combination, for TSEs and/or single or multicellular parasites. The methods involve sterilizing one or more tissues with irradiation.
    Type: Application
    Filed: July 16, 2007
    Publication date: April 3, 2008
    Inventors: Wilson Burgess, William Drohan, Martin MacPhee, David Mann
  • Publication number: 20080033333
    Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 7, 2008
    Inventors: Martin MacPhee, Dawson Beall